PD-L1 testing based on SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion
Por:
Peg, V, Lopez-Garcia, M, Comerma, L, Peiro, G, Garcia-Caballero, T, Lopez, A, Suarez-Gauthier, A, Ruiz, I and Rojo, F
Publicada:
1 abr 2021
Ahead of Print:
1 dic 2020
Resumen:
Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142) antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBC.
Lay abstract
Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Recent discoveries in TNBC have shown that the higher the expression of the surface molecule PD-L1 in the cancer cells, the better the response of patients to immunotherapy. While several tests or diagnostics assays for detecting PD-L1 exist, only the antibody anti-PD-L1 SP142 possesses proven diagnostic value for selecting metastatic TNBC patients eligible for atezolizumab immunotherapy. Throughout the present article, a group of experts discusses how to best carry out the assessment of PD-L1 status with this assay.
Filiaciones:
Peg, V:
Vall dHebron Hosp Univ, Dept Anat Patol, Barcelona Hosp Campus, Barcelona, Spain
Vall dHebron Inst Recerca VHIR, Grp Patol Mol, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Univ Autonoma Barcelona, Bellaterra, Spain
Lopez-Garcia, M:
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Hosp Univ Virgen del Rocio, Serv Anat Patol, Seville, Spain
Comerma, L:
Hosp del Mar, Dept Anat Patol, Barcelona, Spain
:
Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Dept Patol, Alicante, Spain
Garcia-Caballero, T:
Univ Santiago, Fac Med & Odontol, Dept CienciasMorfol, Santiago De Compostela, Spain
Lopez, A:
Complejo Hosp Univ A Coruna, Serv Anat Patol, Biobanco INIBIC, La Coruna, Spain
Suarez-Gauthier, A:
Hosp Univ HM Sanchinarro, Dept Anat Patol, Lab Dianas Terapeut, Madrid, Spain
Ruiz, I:
Hosp Univ Donostia, Serv Patol, Donostia San Sebastian, Spain
Rojo, F:
Fdn Jimenez Diaz, CIBERONC, IIS, Serv Anat Patol, Madrid, Spain
Green Published, Hybrid Gold
|